Focus on biosimilar etanercept – bioequivalence and interchangeability

BACKGROUND: The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015, and HD203 produced relevant changes in the management of rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis due to the considerably lower cost of these products and the consequent saving...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantini, Fabrizio, Benucci, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121755/
https://www.ncbi.nlm.nih.gov/pubmed/30214149
http://dx.doi.org/10.2147/BTT.S126854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121755/
https://www.ncbi.nlm.nih.gov/pubmed/30214149
http://dx.doi.org/10.2147/BTT.S126854

Ejemplares similares